OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacology & Therapeutics is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Editorial Board	409
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	407
Adenosine receptor signalling as a driver of pulmonary fibrosis	340
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	270
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	263
Treatment strategies for leptomeningeal disease in patients with breast cancer	250
Inflammation, lipids, and pain in vulvar disease	225
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	206
Matrikines in the skin: Origin, effects, and therapeutic potential	190
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	183
Unfolded protein responses: Dynamic machinery in wound healing	164
SGLT2 inhibitors: Do they have antiarrhythmic properties?	162
Non-canonical G protein signaling	149
Collateral lethality: A unique type of synthetic lethality in cancers	116
Treatment approaches for alcohol use disorder with metabolic dysfunction	114
Potential neonatal toxicity of new psychoactive substances	114
The role of macrophages in asthma-related fibrosis and remodelling	110
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	109
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	108
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	107
Endothelial dysfunction as a complication of anti-cancer therapy	106
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	105
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	104
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	103
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	99

Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	97
Boron in cancer therapeutics: An overview	95
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	93
Editorial Board	85
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	85
TAAR1 as an emerging target for the treatment of psychiatric disorders	85
Management of drug-resistant hypertension as a heterogeneous disorder	85
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	83
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	83
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	83
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	80
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	80
Dysregulation of metabolic pathways in pulmonary fibrosis	79
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	78
Editorial Board	78
Editorial Board	77
N6-methyladenosine (m6A) RNA methylation: a potential clinical therapeutic target in cardiocerebrovascular diseases	76
PGRMC1: An enigmatic heme-binding protein	74
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	73
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	72
Pharmacological treatment of cardiogenic shock – A state of the art review	71
Review: Sex-related differences in the treatment of cardiac arrhythmia	71
Natural products that alleviate depression: The putative role of autophagy	70
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	70
Bispecific antibodies for the treatment of neuroblastoma	68
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	68
DNA methylation in cell plasticity and malignant transformation in liver diseases	67
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	67
A dive into the untapped potential of marine compounds in counteracting neurodegeneration	67
Stabilizing the neural barrier – A novel approach in pain therapy	66
Unravelling the complexity of cancer premetastatic niche - Mechanistic insights and clinical therapies	65
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	64
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	64
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	63
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	62
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	60
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	60
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	60